154 related articles for article (PubMed ID: 9933104)
1. Direct and indirect T cell priming by dendritic cell vaccines.
Cayeux S; Richter G; Becker C; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1999 Jan; 29(1):225-34. PubMed ID: 9933104
[TBL] [Abstract][Full Text] [Related]
2. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
Paglia P; Chiodoni C; Rodolfo M; Colombo MP
J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
[TBL] [Abstract][Full Text] [Related]
3. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
[TBL] [Abstract][Full Text] [Related]
5. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
Specht JM; Wang G; Do MT; Lam JS; Royal RE; Reeves ME; Rosenberg SA; Hwu P
J Exp Med; 1997 Oct; 186(8):1213-21. PubMed ID: 9334360
[TBL] [Abstract][Full Text] [Related]
7. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
8. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.
Porgador A; Irvine KR; Iwasaki A; Barber BH; Restifo NP; Germain RN
J Exp Med; 1998 Sep; 188(6):1075-82. PubMed ID: 9743526
[TBL] [Abstract][Full Text] [Related]
9. Peptide-pulsed splenic dendritic cells prime long-lasting CD8(+) T cell memory in the absence of cross-priming by host APC.
Livingstone AM; Kuhn M
Eur J Immunol; 2002 Jan; 32(1):281-90. PubMed ID: 11782019
[TBL] [Abstract][Full Text] [Related]
10. Decreased generation of anti-tumor immunity after intrasplenic immunization.
Cayeux S; Qin Z; Dörken B; Blankenstein T
Eur J Immunol; 2001 May; 31(5):1392-9. PubMed ID: 11465096
[TBL] [Abstract][Full Text] [Related]
11. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo.
Böhm W; Schirmbeck R; Elbe A; Melber K; Diminky D; Kraal G; van Rooijen N; Barenholz Y; Reimann J
J Immunol; 1995 Oct; 155(7):3313-21. PubMed ID: 7561024
[TBL] [Abstract][Full Text] [Related]
12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
14. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts.
Nair SK; Snyder D; Rouse BT; Gilboa E
Int J Cancer; 1997 Mar; 70(6):706-15. PubMed ID: 9096653
[TBL] [Abstract][Full Text] [Related]
15. Gamma delta T cells in the pathobiology of murine acute graft-versus-host disease. Evidence that gamma delta T cells mediate natural killer-like cytotoxicity in the host and that elimination of these cells from donors significantly reduces mortality.
Ellison CA; MacDonald GC; Rector ES; Gartner JG
J Immunol; 1995 Nov; 155(9):4189-98. PubMed ID: 7594574
[TBL] [Abstract][Full Text] [Related]
16. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.
Schoenberger SP; Jonges LE; Mooijaart RJ; Hartgers F; Toes RE; Kast WM; Melief CJ; Offringa R
Cancer Res; 1998 Jul; 58(14):3094-100. PubMed ID: 9679976
[TBL] [Abstract][Full Text] [Related]
17. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
18. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
19. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
20. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
